Our colleagues at the UK SMC are hosting a media briefing to present the results of the Phase 3 trial into the AstraZeneca/Oxford COVID vaccine.
Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% per cent effective when combining data from two dosing regimens. In the two different dose regimens vaccine efficacy was 90 per cent in one and 62 per cent in the other
Prof Andrew Pollard, Director of the Oxford Vaccine Group, Department of Paediatrics, University of Oxford
Prof Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute, Nuffield Department of Medicine, University of Oxford
Prof Louise Richardson, Vice Chancellor of the University of Oxford
Pascal Soriot, Chief Executive Officer, AstraZeneca
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca
Pam Cheng, Executive Vice President, Operations and Information Technology, AstraZeneca